<!--?xml version="1.0" encoding="utf-8"?--><!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd"><html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8">
        <!-- AppResources meta begin -->
        <script type="text/javascript">var ncbi_startTime = new Date();</script>
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="">

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="pmc"><meta name="ncbi_pdid" content="article"><meta name="ncbi_acc" content=""><meta name="ncbi_domain" content="plosone"><meta name="ncbi_report" content="record"><meta name="ncbi_type" content="fulltext"><meta name="ncbi_objectid" content=""><meta name="ncbi_pcid" content="/articles/PMC3568070/"><meta name="ncbi_app" content="pmc">
        <!-- Logger end -->
        
        <title>Proresolution Lipid Mediators in Multiple Sclerosis — Differential, Disease Severity-Dependent Synthesis — A Clinical Pilot Trial</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css"><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE"><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3568070/"><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/"><meta name="citation_journal_title" content="PLoS ONE"><meta name="citation_title" content="Proresolution Lipid Mediators in Multiple Sclerosis — Differential, Disease Severity-Dependent Synthesis — A Clinical Pilot Trial"><meta name="citation_authors" content="Harald Prüss, Berit Rosche, Aaron B. Sullivan, Benedikt Brommer, Oliver Wengert, Karsten Gronert, Jan M. Schwab"><meta name="citation_date" content="2013"><meta name="citation_issue" content="2"><meta name="citation_volume" content="8"><meta name="citation_doi" content="10.1371/journal.pone.0055859"><meta name="citation_abstract_html_url" content="/pmc/articles/PMC3568070/?report=abstract"><meta name="citation_pmid" content="23409068"><meta name="DC.Title" content="Proresolution Lipid Mediators in Multiple Sclerosis — Differential, Disease Severity-Dependent Synthesis — A Clinical Pilot Trial"><meta name="DC.Type" content="Text"><meta name="DC.Publisher" content="Public Library of Science"><meta name="DC.Contributor" content="Harald Prüss"><meta name="DC.Contributor" content="Berit Rosche"><meta name="DC.Contributor" content="Aaron B. Sullivan"><meta name="DC.Contributor" content="Benedikt Brommer"><meta name="DC.Contributor" content="Oliver Wengert"><meta name="DC.Contributor" content="Karsten Gronert"><meta name="DC.Contributor" content="Jan M. Schwab"><meta name="DC.Date" content="2013"><meta name="DC.Identifier" content="10.1371/journal.pone.0055859"><meta name="DC.Language" content="en"><meta property="og:title" content="Proresolution Lipid Mediators in Multiple Sclerosis — Differential, Disease Severity-Dependent Synthesis — A Clinical Pilot Trial"><meta property="og:type" content="article"><meta property="og:description" content="The severity and longevity of inflammation is controlled by endogenous counter-regulatory signals. Among them are long-chain polyunsaturated fatty acid (PUFA)-derived lipid mediators, which promote the resolution of inflammation, an active process for ..."><meta property="og:url" content="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3568070/"><meta property="og:site_name" content="PubMed Central (PMC)"><meta property="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/pmc-logo-share.png"><meta name="twitter:card" content="summary"><meta name="twitter:site" content="@ncbi"><meta name="ncbi_feature" content="associated_data"><link rel="stylesheet" href="/corehtml/pmc/css/3.14.1/pmc.min.css" type="text/css"><link rel="stylesheet" href="/corehtml/pmc/css/3.14.1/pmc_extras_prnt.min.css" type="text/css" media="print"><script type="text/javascript" src="/corehtml/pmc/js/common.min.js">//</script><script type="text/javascript" src="/corehtml/pmc/js/NcbiTagServer.min.js">//</script><meta name="citationexporter" content="backend:'https://api.ncbi.nlm.nih.gov/lit/ctxp/v1/pmc/'"><script type="text/javascript" src="https://www.ncbi.nlm.nih.gov/corehtml/pmc/ctxp/jquery.citationexporter.min.js">//</script><link rel="stylesheet" href="https://www.ncbi.nlm.nih.gov/corehtml/pmc/ctxp/citationexporter.css" type="text/css"><script type="text/javascript">window.name="mainwindow";</script><style type="text/css">.pmc-wm {background:transparent repeat-y top left;background-image:url(/corehtml/pmc/pmcgifs/wm-plosone.gif);background-size: auto, contain}</style><style type="text/css">.print-view{display:block}</style><style type="text/css">
        div.pmc_para_cit li.highlight,
        div.pmc_para_cit li.highlight .one_line_source
        { background: #E0E0E0; }
        a.bibr.highlight { background: #E0E0E0; } 
      </style><meta name="cited_in_systematic_reviews" content=""><link rel="alternate" type="application/epub+zip" href="/pmc/articles/PMC3568070/epub/"><link rel="alternate" type="application/pdf" href="/pmc/articles/PMC3568070/pdf/pone.0055859.pdf">

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico"><meta name="ncbi_phid" content="8A1AEAA9E8E35CA10000000008C708C7.m_8">
<meta name="referrer" content="origin-when-cross-origin"><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4048120/3846471/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/3881636/3579733/4062871/12930/3964959/3855473/4047625/3854974/3854955/4076335/4128070/9685/3549676/3609192/3609193/3609213/3395586/4143404.css"><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/css/3411343/3882866/4157116.css" media="print"><script async="1" src="https://www.google-analytics.com/analytics.js"></script><style type="text/css">.ncbi-alerts { background: none repeat scroll 0% 0% #671414;color: #fff;padding: .231em 1.231em;}.ncbi-alerts p { color: #fff; }.ncbi-alerts a, .ncbi-alerts a:visited {color: #fff; background: none;}.ncbi-alerts p {margin: 1em 0;padding: 0 0 0 1.5em; }.ncbi-alerts p:nth-child(1) {background-image: url('/core/icons/information.png');background-position: left top;background-repeat: no-repeat }.ncbi-alerts.subclosed p:nth-child(1) {background-image: url('/core/alerts/warning.png');}.ncbi-alerts.subclosed p { padding-left: 2em;}.ncbi-alerts.pubmed, .ncbi-alerts.pubmed p {background-color: #97B0C8; color: #000;}.ncbi-alerts a { text-decoration: underline !important; }.ncbi-alerts.pubmed a, .ncbi-alerts.pubmed a:visited { color: #000; }.ncbi-alerts, .ncbi-alerts p {background-color: #97B0C8; color: #000;}.ncbi-alerts a, .ncbi-alerts a:visited { color: #000; }</style></head>
    <body class="article" id="ui-ncbiexternallink-4">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	&lt;p class="nojs"&gt;
	&lt;strong&gt;Warning:&lt;/strong&gt;
	The NCBI web site requires JavaScript to function. 
	&lt;a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank"&gt;more...&lt;/a&gt;
	&lt;/p&gt;
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list ui-ncbibasicmenu orientation_hort" id="navcontent" role="menubar"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt" role="presentation"><a class="ui-ncbimenu-link-first" href="/" role="menuitem" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo"></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset" role="presentation"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources" tabindex="-1" role="menuitem">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first" role="presentation"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto" tabindex="-1" role="menuitem">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi" style="top: -0.4em;"><iframe src="https://eutils.ncbi.nlm.nih.gov/entrez/eutils/emyncbi.fcgi?cmd=htmlportal&amp;currenturl=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3568070%2F" style="border:none; height:2.5em; width:40em;" scrolling="no"></iframe></div></div>
                            <div class="header" style="margin-bottom: 0px;">
    <div class="res_logo">
  <h1 class="img_logo"><a href="/pmc/" class="pmc_logo offscreen">PMC</a></h1>
  <div class="NLMLogo">
    <a href="https://www.nlm.nih.gov/" title="US National Library of Medicine">US National Library of Medicine</a>
    <br>
    <a href="https://www.nih.gov/" title="National Institutes of Health">National Institutes of Health</a>
  </div>
</div>
    <div class="search"><form method="get" action="/pmc/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="pmc" selected="selected" class="last" data-ac_dict="pmc-search-autocomplete">PMC</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc" data-ac_dict="pmc-search-autocomplete">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><div class="jig-ncbiclearbutton-wrap ui-ncbiclearbutton-wrap box-shadow"><input type="text" name="term" id="term" title="Search PMC. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'pmc-search-autocomplete',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'yes'" aria-haspopup="true" aria-autocomplete="list" role="textbox"><a class="reset" href="#" style="visibility: hidden;"><img src="/core/jig/1.14.8/img/clear.png" alt="Clear input"></a></div></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/pmc/advanced/">Advanced</a>
                    </li><li>
                        <a href="/pmc/journals/">Journal list</a>
                    </li><li class="help">
                        <a target="_blank" href="/books/NBK3825/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <div class="container">
    <div id="maincontent" class="content eight_col col">
        <div class="navlink-box">
            <ul class="page-breadcrumbs inline_list small"><li class="journal-list"><a href="/pmc/journals/" class="navlink">Journal List</a></li><li class="archive"><a class="navlink" href="/pmc/journals/440/">PLoS One</a></li><li class="issue-page"><a class="navlink" href="/pmc/issues/219104/">v.8(2); 2013</a></li><li class="accid">PMC3568070</li></ul>
        </div>

        <!-- Journal banner -->
        <div class="pmc-page-banner whole_rhythm"><div><img src="/corehtml/pmc/pmcgifs/logo-plosone.gif" alt="Logo of plosone" usemap="#logo-imagemap"><map id="logo-imagemap" name="logo-imagemap"><area shape="rect" coords="0,0,438,55" alt="PLoS One" title="PLoS One" href="http://www.plosone.org/" ref="reftype=publisher&amp;article-id=3568070&amp;issue-id=219104&amp;journal-id=440&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A" target="pmc_ext"><area shape="rect" coords="0,56,104,74" alt="View this Article" title="View this Article" href="//dx.doi.org/10.1371/journal.pone.0055859" ref="reftype=publisher&amp;article-id=3568070&amp;issue-id=219104&amp;journal-id=440&amp;FROM=Article%7CBanner&amp;TO=Content%20Provider%7CArticle%7CFullText" target="pmc_ext"><area shape="rect" coords="106,56,202,74" alt="Submit to PLoS" title="Submit to PLoS" href="http://www.plosone.org/static/checklist.action" ref="reftype=publisher&amp;article-id=3568070&amp;issue-id=219104&amp;journal-id=440&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A" target="pmc_ext"><area shape="rect" coords="204,56,302,74" alt="Get E-mail Alerts" title="Get E-mail Alerts" href="http://journals.plos.org/alerts" ref="reftype=publisher&amp;article-id=3568070&amp;issue-id=219104&amp;journal-id=440&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A" target="pmc_ext"><area shape="rect" coords="304,56,374,74" alt="Contact Us" title="Contact Us" href="http://www.plosone.org/static/contact.action" ref="reftype=publisher&amp;article-id=3568070&amp;issue-id=219104&amp;journal-id=440&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A" target="pmc_ext"><area shape="rect" coords="440,0,500,55" alt="Public Library of Science (PLoS)" title="Public Library of Science (PLoS)" href="http://www.plos.org/" ref="reftype=publisher&amp;article-id=3568070&amp;issue-id=219104&amp;journal-id=440&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A" target="pmc_ext"></map></div> </div>
        
        <!--component id='MainPortlet' label='search-reference'/-->
        
        <!-- Book content -->
        <div class="">
            
        
            
            <div class="hide-overflow article lit-style content pmc-wm slang-all page-box"><!--main-content--><div class="jig-ncbiinpagenav" data-jigconfig="smoothScroll: false, allHeadingLevels: ['h2'], headingExclude: ':hidden'" id="ui-ncbiinpagenav-1"><div class="fm-sec half_rhythm no_top_margin"><div class="fm-citation half_rhythm no_top_margin clearfix"><div class="inline_block eight_col va_top"><div><div><span class="cit"><span role="menubar"><a href="#" role="menuitem" aria-expanded="false" aria-haspopup="true">PLoS One</a></span>. 2013; 8(2): e55859. </span></div><div><span class="fm-vol-iss-date">Published online 2013 Feb 8. </span>  <span class="doi">doi:&nbsp;<a href="//dx.doi.org/10.1371%2Fjournal.pone.0055859" target="pmc_ext" ref="reftype=other&amp;article-id=3568070&amp;issue-id=219104&amp;journal-id=440&amp;FROM=Article%7CFront%20Matter&amp;TO=Content%20Provider%7CCrosslink%7CDOI">10.1371/journal.pone.0055859</a></span></div></div></div><div class="inline_block four_col va_top show-overflow align_right"><div class="fm-citation-ids"><div class="fm-citation-pmcid"><span class="fm-citation-ids-label">PMCID: </span><span>PMC3568070</span></div><div class="fm-citation-pmid">PMID: <a href="/pubmed/23409068">23409068</a></div></div></div></div><h1 class="content-title">Proresolution Lipid Mediators in Multiple Sclerosis — Differential, Disease Severity-Dependent Synthesis — A Clinical Pilot Trial</h1><div class="half_rhythm"><div class="contrib-group fm-author"><a href="/pubmed/?term=Pr%26%23x000fc%3Bss%20H%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=23409068" class="affpopup" co-rid="_co_idm140089076962800" co-class="co-affbox">Harald Prüss</a>,<sup>#</sup><sup>
1
,</sup><sup>
*
</sup> <a href="/pubmed/?term=Rosche%20B%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=23409068" class="affpopup" co-rid="_co_idm140089072072096" co-class="co-affbox">Berit Rosche</a>,<sup>#</sup><sup>
1
</sup> <a href="/pubmed/?term=Sullivan%20AB%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=23409068" class="affpopup" co-rid="_co_idm140089075690720" co-class="co-affbox">Aaron B. Sullivan</a>,<sup>#</sup><sup>
2
</sup> <a href="/pubmed/?term=Brommer%20B%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=23409068" class="affpopup" co-rid="_co_idm140089070179776" co-class="co-affbox">Benedikt Brommer</a>,<sup>
1
</sup> <a href="/pubmed/?term=Wengert%20O%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=23409068" class="affpopup" co-rid="_co_idm140089080050384" co-class="co-affbox">Oliver Wengert</a>,<sup>
1
</sup> <a href="/pubmed/?term=Gronert%20K%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=23409068" class="affpopup" co-rid="_co_idm140089075830992" co-class="co-affbox">Karsten Gronert</a>,<sup>
2
,</sup><sup>
¶
</sup> and  <a href="/pubmed/?term=Schwab%20JM%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=23409068" class="affpopup" co-rid="_co_idm140089077288000" co-class="co-affbox">Jan M. Schwab</a><sup>
1
,</sup><sup>
*
,</sup><sup>
¶
</sup></div><div style="display:none" class="contrib-group aff-tip"><div id="_co_idm140089076962800"><h3 class="no_margin">Harald Prüss</h3><p>  <sup>1</sup>  Department of Neurology &amp; Experimental Neurology, Charité University Medicine Berlin, Berlin, Germany,   </p><div>Find articles by <a href="/pubmed/?term=Pr%26%23x000fc%3Bss%20H%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=23409068">Harald Prüss</a></div></div><div id="_co_idm140089072072096"><h3 class="no_margin">Berit Rosche</h3><p>  <sup>1</sup>  Department of Neurology &amp; Experimental Neurology, Charité University Medicine Berlin, Berlin, Germany,   </p><div>Find articles by <a href="/pubmed/?term=Rosche%20B%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=23409068">Berit Rosche</a></div></div><div id="_co_idm140089075690720"><h3 class="no_margin">Aaron B. Sullivan</h3><p>  <sup>2</sup>  Vision Science Program, School of Optometry, University of California, Berkeley, California, United States of America,   </p><div>Find articles by <a href="/pubmed/?term=Sullivan%20AB%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=23409068">Aaron B. Sullivan</a></div></div><div id="_co_idm140089070179776"><h3 class="no_margin">Benedikt Brommer</h3><p>  <sup>1</sup>  Department of Neurology &amp; Experimental Neurology, Charité University Medicine Berlin, Berlin, Germany,   </p><div>Find articles by <a href="/pubmed/?term=Brommer%20B%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=23409068">Benedikt Brommer</a></div></div><div id="_co_idm140089080050384"><h3 class="no_margin">Oliver Wengert</h3><p>  <sup>1</sup>  Department of Neurology &amp; Experimental Neurology, Charité University Medicine Berlin, Berlin, Germany,   </p><div>Find articles by <a href="/pubmed/?term=Wengert%20O%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=23409068">Oliver Wengert</a></div></div><div id="_co_idm140089075830992"><h3 class="no_margin">Karsten Gronert</h3><p>  <sup>2</sup>  Vision Science Program, School of Optometry, University of California, Berkeley, California, United States of America,   </p><div>Find articles by <a href="/pubmed/?term=Gronert%20K%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=23409068">Karsten Gronert</a></div></div><div id="_co_idm140089077288000"><h3 class="no_margin">Jan M. Schwab</h3><p>  <sup>1</sup>  Department of Neurology &amp; Experimental Neurology, Charité University Medicine Berlin, Berlin, Germany,   </p><div>Find articles by <a href="/pubmed/?term=Schwab%20JM%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=23409068">Jan M. Schwab</a></div></div></div></div><div class="contrib-group half_rhythm fm-editor">Patricia T. Bozza, <span class="fm-role">Editor</span><sup></sup></div><div class="fm-panel half_rhythm"><div class="togglers"><a href="#" class="pmctoggle" rid="idm140089081471184_ai idm140089076962928_ai idm140089078695552_ai">Author information</a> <a href="#" class="pmctoggle" rid="idm140089081471184_an">Article notes</a> <a href="#" class="pmctoggle" rid="idm140089081471184_cpl">Copyright and License information</a> <a href="/pmc/about/disclaimer/">Disclaimer</a></div><div class="fm-authors-info fm-panel hide half_rhythm" id="idm140089081471184_ai" style="display:none"><div class="fm-affl" lang="en" id="aff1">  <sup>1</sup>  Department of Neurology &amp; Experimental Neurology, Charité University Medicine Berlin, Berlin, Germany,   </div><div class="fm-affl" lang="en" id="aff2">  <sup>2</sup>  Vision Science Program, School of Optometry, University of California, Berkeley, California, United States of America,   </div><div class="fm-affl" lang="en" id="edit1">  Fundação Oswaldo Cruz, Brazil,   </div><div><sup>#</sup>Contributed equally.</div><div id="cor1">* E-mail: <a href="mailto:dev@null" data-email="ed.etirahc@bawhcs.naj" class="oemail">ed.etirahc@bawhcs.naj</a> (JMS); <a href="mailto:dev@null" data-email="ed.etirahc@sseurp.dlarah" class="oemail">ed.etirahc@sseurp.dlarah</a> (HP)</div><div id="idm140089080018880"><strong>Competing Interests: </strong>There are no financial interests. The funding from “Bayer-Schering” is a restricted research grant, covering some costs for laboratory material. This grant to BR does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials.</div><div><p id="__p2" class="p p-first-last">Conceived and designed the experiments: HP BR KG JS. Performed the experiments: HP BR ABS BB OW KG JS. Analyzed the data: HP BR ABS BB KG JS. Contributed reagents/materials/analysis tools: HP BR ABS BB OW KG JS. Wrote the paper: HP BR ABS BB OW KG JS.</p></div><div id="fn1">¶ These authors also contributed equally to this work.</div></div><div class="fm-article-notes fm-panel hide half_rhythm" id="idm140089081471184_an" style="display:none"><div class="fm-pubdate half_rhythm">Received 2012 Jul 23; Accepted 2013 Jan 3.</div></div><div class="permissions fm-panel half_rhythm hide" id="idm140089081471184_cpl" style="display:none"><div class="fm-copyright half_rhythm"><a href="/pmc/about/copyright/">Copyright</a> © 2013 Prüss et al</div><div class="license half_rhythm">This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.</div></div></div><div id="pmclinksbox" class="links-box whole_rhythm"><div class="fm-panel"><div>This article has been <a href="/pmc/articles/PMC3568070/citedby/">cited by</a> other articles in PMC.</div></div></div></div><div class="sec"></div><div id="ass-data" class="tsec fm-sec whole_rhythm" data-section="Featured_PMC_Datacitation"><div class="goto jig-ncbiinpagenav-goto-container"><span role="menubar"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="menuitem" aria-expanded="false" aria-haspopup="true">Go to:</a></span></div><h2 class="ui-helper-clearfix" id="ui-ncbiinpagenav-heading-3">Associated Data</h2><dl data-count="1" class="box-data-suppmats whole_rhythm no_bottom_margin"><dt><a href="#" rid="data-suppmats" data-ga-action="click_feat_toggler" data-ga-label="Supplementary Materials" class="pmctoggle">Supplementary Materials</a></dt><dd id="data-suppmats" style="display: none;"><div class="half_rhythm"><div class="caption half_rhythm no_bottom_margin"><strong>Table S1: </strong>MRM parameters and analytes<p>(DOC)</p></div><div><a href="/pmc/articles/PMC3568070/bin/pone.0055859.s001.doc" data-ga-action="click_feat_suppl">pone.0055859.s001.doc</a><span style="color:gray"> (53K)</span></div><div class="small guid">GUID:&nbsp;68F6C5C0-91D8-4CCB-84C3-77478569DDA6</div></div></dd></dl></div><div id="idm140089062296448" lang="en" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="idm140089062296448title">Abstract</h2><!--article-meta--><div><div id="__sec1" class="sec sec-first"><h3 id="__sec1title">Background</h3><p id="__p4" class="p p-first-last">The severity and longevity of inflammation is controlled by endogenous counter-regulatory signals. Among them are long-chain polyunsaturated fatty acid (PUFA)-derived lipid mediators, which promote the resolution of inflammation, an active process for returning to tissue homeostasis.</p></div><div id="__sec2" class="sec"><h3 id="__sec2title">Objective</h3><p id="__p5" class="p p-first-last">To determine whether endogenous production of lipid-derived resolution agonists is regulated differentially in patients with highly active and less active multiple sclerosis (MS).</p></div><div id="__sec3" class="sec"><h3 id="__sec3title">Design</h3><p id="__p6" class="p p-first-last">Matched-pairs study in University hospital Neurology department.</p></div><div id="__sec4" class="sec"><h3 id="__sec4title">Patients</h3><p id="__p7" class="p p-first-last">Based on clinical (relapse frequency) and paraclinical (MRI lesions, contrast enhancement) criteria, 10 pairs of age- and sex-matched patients with relapsing-remitting MS were assigned either to a group with highly active or less active MS. Lipid mediators were quantified in serum and cerebrospinal fluid using LC-MS/MS-based lipidomics.</p></div><div id="__sec5" class="sec"><h3 id="__sec5title">Results</h3><p id="__p8" class="p p-first-last">Levels of the key arachidonic (ω-6) and docosahexaenoic acid (ω-6)-derived mediators prostaglandins (PG), leukotrienes, hydroxyeicosatetraenoic acids (HETE) and resolution agonists lipoxin A<sub>4</sub> (LXA<sub>4</sub>), resolvin D1 (RvD1) and neuroprotectin D1 (NPD1) were quantified. In the patient group with highly active MS, 15-HETE and PGE<sub>2</sub> were increased, which are products of the 15-lipoxygenase and cyclooxygenase pathways. The proresolution mediator RvD1 was significantly upregulated and NPD1 was detected in the highly active group only. LXA<sub>4</sub> levels were not increased in patients with highly active MS.</p></div><div id="__sec6" class="sec sec-last"><h3 id="__sec6title">Conclusions</h3><p id="__p9" class="p p-first-last">Lipid mediator pathways are regulated differentially in the cerebrospinal fluid of MS patients, depending on disease severity. Non-exhaustive or possibly ‘delayed’ resolution pathways may suggest a defective resolution program in patients with highly active MS. Longitudinal analyses are required to hetero-typify this differential resolution capacity, which may be associated with disease progression, longevity and eventual termination.</p></div></div></div><div id="s1" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="s1title">Introduction</h2><p id="__p10" class="p p-first">Resolution of inflammation is an active endogenous process necessary for the termination of inflammatory and autoimmune diseases – inflammation does not just passively fizzle out. <a href="#pone.0055859-Serhan1" rid="pone.0055859-Serhan1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_680261109" role="button" aria-expanded="false" aria-haspopup="true">[1]</a> It is a tightly controlled, directed tissue response orchestrated by cellular and humoral factors such as PUFA (omega- 3 (ω-3), -6 (ω-6))-derived lipid mediators. <a href="#pone.0055859-Serhan1" rid="pone.0055859-Serhan1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_680261125" role="button" aria-expanded="false" aria-haspopup="true">[1]</a>–<a href="#pone.0055859-Nathan1" rid="pone.0055859-Nathan1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_680261126" role="button" aria-expanded="false" aria-haspopup="true">[3]</a> Early interventional MS trials supplementing ω-3 and ω-6 were based on socio-epidemiological studies demonstrating that the risk of MS is high in countries with a high intake of saturated fatty acids and low in countries with a high intake of poly-unsaturated fatty acids (PUFAs). <a href="#pone.0055859-Bates1" rid="pone.0055859-Bates1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_680261116" role="button" aria-expanded="false" aria-haspopup="true">[4]</a> This however remains controversial, since some ω-3 and -6-derived lipid mediators have revealed anti-inflammatory and others pro-inflammatory functions. <a href="#pone.0055859-Serhan1" rid="pone.0055859-Serhan1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_680261120" role="button" aria-expanded="false" aria-haspopup="true">[1]</a>.</p><p id="__p11">It is noteworthy that arachidonic acid (AA)-derived prostaglandins such as prostaglandin E<sub>2</sub> (PGE<sub>2</sub>) were originally identified primarily for their potent pro-inflammatory effect, promoting edema formation and oxidative toxicity, but they also promote T-helper (TH)1 and TH17 cell generation, which mediate tissue damage and inflammation. <a href="#pone.0055859-Yao1" rid="pone.0055859-Yao1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_680261110" role="button" aria-expanded="false" aria-haspopup="true">[5]</a> Interference with its receptor suppresses disease progression in mice subjected to experimental autoimmune encephalomyelitis (EAE). <a href="#pone.0055859-Yao1" rid="pone.0055859-Yao1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_680261115" role="button" aria-expanded="false" aria-haspopup="true">[5]</a> Elevated levels of PGE<sub>2</sub> were detected in EAE lesions and in the cerebrospinal fluid (CSF) of MS patients. <a href="#pone.0055859-Greco1" rid="pone.0055859-Greco1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_680261112" role="button" aria-expanded="false" aria-haspopup="true">[6]</a> On the other hand, AA is also a substrate for the bifunctional, anti-inflammatory and pro-resolutive molecule LXA<sub>4</sub>. <a href="#pone.0055859-Chiang1" rid="pone.0055859-Chiang1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_680261118" role="button" aria-expanded="false" aria-haspopup="true">[7]</a>, <a href="#pone.0055859-Schwab1" rid="pone.0055859-Schwab1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_680261129" role="button" aria-expanded="false" aria-haspopup="true">[8]</a> The discovery of ω-3 and ω-6 as substrates for resolution agonists such as lipoxins, protectins and resolvins, which are generated by distinct transcellular pathways, provided a consistent rationale for the underlying biological functions. <a href="#pone.0055859-Serhan1" rid="pone.0055859-Serhan1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_680261113" role="button" aria-expanded="false" aria-haspopup="true">[1]</a> Deficiencies in these resolution pathways can prolong inflammation and lead to the failure of tissue to return to homeostasis. <a href="#pone.0055859-Serhan1" rid="pone.0055859-Serhan1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_680261111" role="button" aria-expanded="false" aria-haspopup="true">[1]</a> The recent identification of resolution agonists supports the notion that resolution is an active process independent of inflammation. <a href="#pone.0055859-Gilroy1" rid="pone.0055859-Gilroy1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_680261106" role="button" aria-expanded="false" aria-haspopup="true">[2]</a>.</p><p id="__p12" class="p p-last">However, the role of these molecules in MS pathology remains elusive. We therefore used LC-MS mass spectrometry to investigate the synthesis of the ω-3 and ω-6-derived resolution agonists in CSF and in serum samples of MS patients with highly and less active disease.</p></div><div id="s2" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="s2title">Methods</h2><div id="s2a" class="sec sec-first"><h3 id="s2atitle">Patients</h3><p id="__p13" class="p p-first-last">20 selected patients with a diagnosis of relapsing-remitting MS or clinically isolated syndrome according to the revised McDonald criteria from 2011 <a href="#pone.0055859-Polman1" rid="pone.0055859-Polman1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_680261128" role="button" aria-expanded="false" aria-haspopup="true">[9]</a> were age- and sex-matched for highly or less active disease severity and enrolled in this cohort study. The trial considered samples from two treating Charité Neurology Centers (Campus Mitte and Campus Virchow). CSF and serum specimens were collected, immediately put on ice and a separate tube snap-frozen and stored in liquid nitrogen, all sample transportation was done on dry ice. According to the German Multiple Sclerosis Consensus Group [MSTKG] severe disease is considered with ≥6 lesions in the initial MRI or a severe clinical presentation at disease onset defined by an Expanded Disability Status Scale (EDSS) of ≥3 (because patients with a clinically isolated syndrome and EDSS ≥3 had a high probability to develop definite MS). Based on these criteria we scored all patients at initial diagnosis for (i) T2-weighted lesions in MRI (0–6 lesions = 1; 7–10 lesions = 2; &gt;10 lesions = 3), (ii) gadolinium enhancing lesions (0 lesions = 1, 1 lesion = 2, &gt;1 lesions = 3), (iii) EDSS (EDSS 0 = 1; EDSS 1–2 = 2; EDSS &gt;2 = 3) and (iv) CSF cell count (normal [&lt;15/3 per µl] = 1, ≤20/3 = 2; &gt;20/3 = 3). Patients with a sum score ≤6 were classified as having less active MS and patients with &gt;6 points as highly active MS. All patients had CSF oligoclonal bands. At time of investigation no patient had concurrent illnesses, was on treatment with steroids, immunosuppressive substances or was receiving diet supplements with long-chain PUFA. The Charité University Hospital ethical committee approved the experiments and all patients gave informed consent for research and publication.</p></div><div id="s2b" class="sec"><h3 id="s2btitle">Lipid Mediator Analysis</h3><p id="__p14" class="p p-first">For endogenous lipid mediator analysis, blinded snap frozen serum and CSF samples were rapidly thawed and immediately combined with two volumes of cold methanol (4°C) containing deuterated internal standards prostaglandin E<sub>2</sub> (PGE<sub>2</sub>-d<sub>4</sub>), 15(S)-hydroxyeicosatetraenoic acid (15(<em>S</em>)-HETE-d<sub>8</sub>) and (leukotriene B<sub>4</sub> LTB<sub>4-</sub>d<sub>4</sub>), arachidonic acid (AA-d8) and docosahexaenoic acid (DHA-d5) (400 pg/each) to calculate the recovery of different classes of oxygenated polyunsaturated fatty acids and their substrates (AA, DHA) (<a href="/pmc/articles/PMC3568070/figure/pone-0055859-g001/" target="figure" class="fig-table-link figpopup" rid-figpopup="pone-0055859-g001" rid-ob="ob-pone-0055859-g001" co-legend-rid="lgnd_pone-0055859-g001"><span>figure 1</span></a>). Lipid autacoids were extracted by solid phase using SampliQ ODS-C18 cartridges (Agilent Technologies, Santa Clara, CA). Endogenous levels of the following lipid mediators were identified and quantified with LC/MS/MS-based lipidomics (<a href="/pmc/articles/PMC3568070/figure/pone-0055859-g001/" target="figure" class="fig-table-link figpopup" rid-figpopup="pone-0055859-g001" rid-ob="ob-pone-0055859-g001" co-legend-rid="lgnd_pone-0055859-g001"><span>figure 1</span></a>): 4-, 7-, 14- and 17-hydroxy-docosahexaenoic acid (4-HDHA, 7-HDHA, 14-HDHA, 17-HDHA), 5-, 12- and 15-hydroxyeicosatetraenoic acid (5-HETE, 12-HETE, 15-HETE), prostaglandin E<sub>2</sub>, D<sub>2</sub> and F<sub>2</sub> (PGE<sub>2</sub>, PGD<sub>2</sub>, PGF<sub>2</sub>), lipoxin A<sub>4</sub> and B<sub>4</sub> (LXA<sub>4</sub>, LXB<sub>4</sub>), leukotriene B<sub>4</sub> (LTB<sub>4</sub>), thromboxane B<sub>2</sub> (TXB<sub>2</sub>), arachidonic acid (AA), docosahexaenoic acid (DHA), eicosapentanoic acid (EPA), resolvin D1 (RvD1), and neuroprotectin D1 (NPD1). <a href="#pone.0055859-Hassan1" rid="pone.0055859-Hassan1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_680261124" role="button" aria-expanded="false" aria-haspopup="true">[10]</a>–<a href="#pone.0055859-GonzalezPeriz1" rid="pone.0055859-GonzalezPeriz1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_680261123" role="button" aria-expanded="false" aria-haspopup="true">[14]</a> In brief, we analyzed extracted samples by a triple-quadrupole linear ion trap LC/MS/MS system (MDS SCIEX 3200 QTRAP) equipped with a Kinetex C18 mini-bore column. The mobile phase was a gradient of A [water/acetonitrile/acetic acid (72:28:0.01, v:v:v)] and B [isopropanol/acetonitrile (60:40, v:v)] with a 450 µl/min flow rate. MS/MS analyses were carried out in negative ion mode and prominent fatty acid metabolites were quantified by multiple reaction monitoring (MRM mode) using established transitions (table S1 and <a href="http://www.lipidmaps.org" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=3568070&amp;issue-id=219104&amp;journal-id=440&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI" target="_blank">www.lipidmaps.org</a>). <a href="#pone.0055859-Hassan1" rid="pone.0055859-Hassan1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_680261121" role="button" aria-expanded="false" aria-haspopup="true">[10]</a> Average recovery rates for internal standards was monohydroxy PUFA (15-HETE) 48±3%, dihydroxy PUFA (LTB<sub>4</sub>/a 5,12-diHETE) 38±2%, trihydroxy PUFA (LXA<sub>4</sub>, a 5,6,15 triHETE) 39±2%, prostaglandins (PGE<sub>2</sub>) 54±2%, AA 21±1% and DHA 15±1%. Linear calibration curves (0.5–1000 pg or 0.01–10 ng for PUFA) and specific LC retention times for each analyte were established with synthetic standards (Cayman Chemical, Ann Arbor, MI). Limits of quantification for specific analytes ranged from 1–50 pg with a signal to noise ratio of &gt;10. Structures were confirmed for selected autacoids by MS/MS analyses using enhanced product ion mode with appropriate selection of the parent ion in quadrupole 1.</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm clearfix" id="pone-0055859-g001" co-legend-rid="lgnd_pone-0055859-g001"><a href="/pmc/articles/PMC3568070/figure/pone-0055859-g001/" target="figure" rid-figpopup="pone-0055859-g001" rid-ob="ob-pone-0055859-g001"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--></a><div data-largeobj="" data-largeobj-link-rid="largeobj_idm140089076650112" class="figure"><a href="/pmc/articles/PMC3568070/figure/pone-0055859-g001/" target="figure" rid-figpopup="pone-0055859-g001" rid-ob="ob-pone-0055859-g001"></a><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=3568070_pone.0055859.g001.jpg" target="tileshopwindow"><div class="ts_bar small" title="Click on image to zoom"></div><img alt="An external file that holds a picture, illustration, etc.
Object name is pone.0055859.g001.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC3568070/bin/pone.0055859.g001.jpg"></a></div><div id="largeobj_idm140089076650112" class="largeobj-link align_right" style="display: none;"><a target="object" href="/pmc/articles/PMC3568070/figure/pone-0055859-g001/?report=objectonly">Open in a separate window</a></div><div class="icnblk_cntnt" id="lgnd_pone-0055859-g001"><div><a class="figpopup" href="/pmc/articles/PMC3568070/figure/pone-0055859-g001/" target="figure" rid-figpopup="pone-0055859-g001" rid-ob="ob-pone-0055859-g001">Figure 1</a></div><!--caption a7--><div class="caption"><!--caption a8--><strong>LC/MS/MS Lipid Mediator Profiling.</strong><p id="__p15">A) MRM profile of 12 eicosanoid and docosanoid synthetic standards (NPD1, 4-HDHA, 17-HDHA, RVD1, PGE<sub>2</sub>, PGD<sub>2</sub>, LTB<sub>4</sub>, 6-trans LTB<sub>4</sub> (C1), 6-trans-12-epi-LTB<sub>4</sub> (C2), 12-HETE, 15-HETE, 5-HETE). B) Representative MRM chromatogram of 15-HETE, PGE<sub>2</sub> and RvD1 from patients with less active MS (black line) and with highly active MS (red line). MRM signals (CPS) were corrected for recovery and cerebrospinal fluid sample size. Calibration curves (1–1000 pg) and specific LC retention times for each compound were established with synthetic standards (Cayman Chemical, Ann Arbor, MI). Structures were confirmed for selected samples by MS/MS analyses using enhanced product ion mode with appropriate selection of the parent ion in quadrupole 1.</p></div></div></div></div><div id="s2c" class="sec sec-last"><h3 id="s2ctitle">Statistical Analysis</h3><p id="__p16" class="p p-first-last">The serum and CSF levels of lipid mediators (mean ± SEM) were compared between the two groups. Wilcoxon matched pairs test of significance (two-tailed) was performed with <em>P</em>&lt;0.05 being considered significant.</p></div></div><div id="s3" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="s3title">Results</h2><p id="__p17" class="p p-first">A total of 20 subjects were enrolled in a matched paired cohort study. The age (mean ± SEM) in the ‘less active’ MS group (31.4 years ±2.5) was not statistically different from the ‘highly active’ group (34.0±2.3). Cohorts were composed of 5 male plus 5 female subjects each. Patients with highly active MS revealed higher (p = 0.0019; Mann-Whitney, two-tailed) numbers of CSF cells (40.2/3±8.6/3 per µl) compared to the less active group (9.4/3±1.97/3 per µl). Furthermore, the number of MS lesions in MRI was about three times higher (p = 0.0015) in the ‘highly active’ group (12.8±3.8) than in the ‘less active’ group (3.4±0.67).</p><p id="__p18">Mass spectrometry analysis of serum and CSF samples was performed blinded and revealed significant differences in lipid mediator levels of both AA and DHA derived lipid mediators (<a href="/pmc/articles/PMC3568070/figure/pone-0055859-g002/" target="figure" class="fig-table-link figpopup" rid-figpopup="pone-0055859-g002" rid-ob="ob-pone-0055859-g002" co-legend-rid="lgnd_pone-0055859-g002"><span>figure 2</span></a>). Differences between disease groups were, however, only confined and specific for the CSF. Thus, no changes were observed in the serum compartment. In the CSF, no differences between disease groups were observed in substrate levels (precursor lipids) of AA (<em>P = </em>0.69) or docosahexaenoic acid (DHA, <em>P = </em>0.69). Here, the CSF levels of AA and DHA correlated closely among all patients (<em>R<sup>2</sup></em> = 0.9). In the active MS group the intermediate, AA-derived molecule 15-hydroxyeicosatetraenoic acid (15-HETE) reached significantly higher levels (4.4 pg/ml ±0.8 [mean ± SEM] vs. 2.2 pg/ml ±0.63, <em>P&lt;</em>0.05), and this was also the case with the pleiotropic inflammatory mediator PGE<sub>2</sub> (1.27 pg/ml ±0.27 vs. 0.65 pg/ml ±0.12, <em>P&lt;</em>0.01), Thromboxanes, leukotrienes and prostaglandin D2 remained unchanged.</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm clearfix" id="pone-0055859-g002" co-legend-rid="lgnd_pone-0055859-g002"><a href="/pmc/articles/PMC3568070/figure/pone-0055859-g002/" target="figure" rid-figpopup="pone-0055859-g002" rid-ob="ob-pone-0055859-g002"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--></a><div data-largeobj="" data-largeobj-link-rid="largeobj_idm140089060362720" class="figure"><a href="/pmc/articles/PMC3568070/figure/pone-0055859-g002/" target="figure" rid-figpopup="pone-0055859-g002" rid-ob="ob-pone-0055859-g002"></a><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=3568070_pone.0055859.g002.jpg" target="tileshopwindow"><div class="ts_bar small" title="Click on image to zoom"></div><img alt="An external file that holds a picture, illustration, etc.
Object name is pone.0055859.g002.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC3568070/bin/pone.0055859.g002.jpg"></a></div><div id="largeobj_idm140089060362720" class="largeobj-link align_right" style=""><a target="object" href="/pmc/articles/PMC3568070/figure/pone-0055859-g002/?report=objectonly">Open in a separate window</a></div><div class="icnblk_cntnt" id="lgnd_pone-0055859-g002"><div><a class="figpopup" href="/pmc/articles/PMC3568070/figure/pone-0055859-g002/" target="figure" rid-figpopup="pone-0055859-g002" rid-ob="ob-pone-0055859-g002">Figure 2</a></div><!--caption a7--><div class="caption"><!--caption a8--><strong>Pro-inflammatory and pro-resolution lipid mediators in CSF of patients with ‘highly active’ versus ‘less active’ MS.</strong><p id="__p19">Released AA is converted into prostaglandins, leukotrienes, thromboxane, lipoxins, and hydroxy-eicosatetraenoic acids (HETEs), collectively termed eicosanoids. Lipoxygenase metabolism of DHA results in the generation of 17-HDHA, the resolvin D series and neuroprotectin D1. (A) Mass spectrometry detection in lumbar CSF suggests that the differences in the brain are very robust as the molecules are produced locally and become diluted during CSF flow. Precursors AA and DHA were similarly present in both disease phenotypes. PGE<sub>2</sub>, 15-HETE and the proresolution agonist RvD1 were significantly increased in patients with highly active MS, and NPD1 was only detectable in this group. (B) Synopsis of lipid mediator synthesis pathways and disease severity-dependent differences in CSF of MS patients. The levels of the precursors AA and DHA correlated closely, suggesting parallel regulation of the lipid mediator metabolism, but they did not correlate with active MS. In contrast, increased CSF levels of PGE<sub>2</sub>, 15-HETE and RvD1 correlated with active MS. Thus, lipid mediator production in active MS is not regulated by the release of precursor molecules but rather likely by the activation/expression of targeted enzymatic oxidation pathways as a specific disease response or component of disease progression.</p></div></div></div><p id="__p20" class="p p-last">Among the anti-inflammatory and proresolutive lipid mediators, lipoxin A<sub>4</sub> (LXA<sub>4</sub>) was not significantly increased in patients with active disease compared to those with inactive disease (<a href="/pmc/articles/PMC3568070/figure/pone-0055859-g002/" target="figure" class="fig-table-link figpopup" rid-figpopup="pone-0055859-g002" rid-ob="ob-pone-0055859-g002" co-legend-rid="lgnd_pone-0055859-g002"><span>figure 2B</span></a>). As the 15-HETE level is enhanced (which serves as marker for the LXA<sub>4</sub> pathway), we cannot exclude the possibility that LXA<sub>4</sub> already metabolized within the snap shot time and that LXA<sub>4</sub> levels were thus underestimated. In contrast, the DHA-derived resolvin D1 (RvD1) was increased in CSF of patients with highly active MS (0.89 pg/ml ±0.41 vs. 0.12 pg/ml ±0.05, <em>P = </em>0.014). Also, the DHA-derived neuroprotectin D1 (NPD1) reached detectable levels only in highly active MS patients. No correlation was found between mediators along the synthesis pathways (e.g. 17-HDHA and RvD1, <em>R<sup>2</sup></em> = 0.025; 15-HETE and LXA<sub>4</sub>, <em>R<sup>2</sup></em> = 0.094) suggesting a non-saturated relationship between substrate and effector molecules.</p></div><div id="s4" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="s4title">Discussion</h2><p id="__p21" class="p p-first">In this first comprehensive analysis of lipid mediator resolution agonists in human CSF we report that patients with ‘highly active’ and ‘less active’ MS not only had a different CSF expression of pro-inflammatory mediators, but also differed in their synthesis of proresolution lipid mediators. We were able to corroborate the elevated PGE<sub>2</sub> and 15-HETE CSF levels that were recently reported in MS patients as a quantitative CSF marker of neuroinflammation and oxidative stress. <a href="#pone.0055859-Greco1" rid="pone.0055859-Greco1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_680261119" role="button" aria-expanded="false" aria-haspopup="true">[6]</a> Importantly, no difference was observed in serum levels of PGE<sub>2</sub> and 15-HETE, suggesting CNS-specific effects. This finding supports the well-established concept of compartmentalized effects in MS, as seen for several biomarkers <a href="#pone.0055859-Awad1" rid="pone.0055859-Awad1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_680261108" role="button" aria-expanded="false" aria-haspopup="true">[15]</a>.Interestingly, we detected a relationship between disease severity and the proresolution mediator RvD1, which has been shown to diminish inflammation caused by oxidative stress <a href="#pone.0055859-Spite1" rid="pone.0055859-Spite1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_680261107" role="button" aria-expanded="false" aria-haspopup="true">[16]</a> and to dampen leukocyte trafficking into and clear macrophages out of inflammation sites. <a href="#pone.0055859-Schwab1" rid="pone.0055859-Schwab1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_680261117" role="button" aria-expanded="false" aria-haspopup="true">[8]</a> Given a dichotomous resolution phenotype in humans controlled by proresolution mediators categorized in ‘early resolvers’ (low initial but persistently increasing) and ‘delayed resolvers’ (high initial but short-lived peak of resolution agonists insufficient to prevent chronic inflammatory disease), the ‘highly active’ cohort might qualify for the ‘delayed resolver’ group, since all CSF samples were derived during or shortly after the inflammatory relapse. <a href="#pone.0055859-Morris1" rid="pone.0055859-Morris1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_680261130" role="button" aria-expanded="false" aria-haspopup="true">[17]</a> Another biological explanation would be that in the ‘highly active’ MS cohort increased CSF cell numbers would represent a higher synthesis capacity of the lipid mediator resolution agonists. In contrast to RvD1, the AA-derived LXA<sub>4</sub> was not significantly upregulated in the CSF of ‘highly active’ MS patients, suggesting a differentially regulated resolution program defining a ω-3 PUFA versus a ω-6 PUFA hierarchy in response to an inflammatory stimulus within a spatio-temporal resolutive context. Furthermore, since endogenous LXA<sub>4</sub> synthesis is limited despite sufficient substrate (15-HETE) which is in line with a defective “lipid mediator class switch” <a href="#pone.0055859-Levy1" rid="pone.0055859-Levy1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_680261127" role="button" aria-expanded="false" aria-haspopup="true">[18]</a>, it might be worthwhile analyzing whether aspirin-triggered epimeric LXA<sub>4</sub> levels can also be boosted in the CSF of MS patients, as has been demonstrated in the serum of healthy subjects taking low-dose aspirin. <a href="#pone.0055859-Chiang1" rid="pone.0055859-Chiang1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_680261122" role="button" aria-expanded="false" aria-haspopup="true">[7]</a> Disruption of 12/15-lipoxygenase (which produces LXA<sub>4</sub>) results in a break of immunological self-tolerance <a href="#pone.0055859-Uderhardt1" rid="pone.0055859-Uderhardt1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_680261114" role="button" aria-expanded="false" aria-haspopup="true">[19]</a>, which is impaired in MS. Thus, increased levels of aspirin-triggered epimeric LXA<sub>4</sub> might support anti-inflammatory/pro-resolutive pathways and thereby be more specific than applying additional substrate by ω-3 &amp; ω-6 PUFA supplemented nutrition.</p><p id="__p22">The measurements reflect the lipid mediator profile at the time of clinical examination. Thus, although using several control metabolites, the technical approach cannot exclude that decreased levels of lipid mediators result from an increased rate of lipid metabolism/inactivation rather than decreased formation. Sample collection was optimized for analysis of frozen material which has repeatedly been shown by us and many other groups to result in robust disease- or inflammation-specific lipid mediator profiles not seen in healthy controls. However, we cannot rule out that class-specific degradation may affect the measured levels of selected analytes in both patient groups. Limited amounts of patient material did not allow for exclusion of any storage-related degradation, as human specimens would have to be spiked with specific labeled analytes.</p><p id="__p23" class="p p-last">The clinical outcome of MS patients might not be determined solely by the levels of pro-inflammatory mediators, which have conceptually dominated diagnostic and interventional approaches in past, but also by a milieu of resolution agonists at the lesion site. Further prospective longitudinal studies are needed to clarify whether clinical disease progression as measured with the Expanded Disability Status Scale (EDSS) correlates with the presence and levels of resolution agonists, thereby influencing disease longevity and eventually its termination.</p></div><div id="s5" class="tsec sec"><a id="supplementary-material-sec"></a><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="s5title">Supporting Information</h2><!--/article/body/sec/--><div class="sec suppmat" id="pone.0055859.s001"><h4>Table S1</h4><p id="__p24">MRM parameters and analytes</p><p id="__p25">(DOC)</p><div class="sup-box half_rhythm" id="idm140089079839120"><a href="/pmc/articles/PMC3568070/bin/pone.0055859.s001.doc" data-ga-action="click_feat_suppl">Click here for additional data file.</a><sup>(53K, doc)</sup></div></div></div><div id="idm140089076814864" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="idm140089076814864title">Acknowledgments</h2><div class="sec"><p id="__p27">We thank Prof. U. Dirnagl for his valuable comments.</p></div></div><div id="idm140089077546400" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="idm140089077546400title">Funding Statement</h2><p>JS is supported by the Berlin-Brandenburg Center for Regenerative Therapies (BCRT, #81717034) and the Wings for Life Spinal Cord Research Foundation, Austria (travel grant). The authors also acknowledge support from the National Institutes of Health (EY022208 and EY016136) to KG and from a restricted research grant covering some costs for laboratory material from “Bayer-Schering” to BR. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</p></div><div id="idm140089076814240" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="idm140089076814240title">References</h2><div class="ref-list-sec sec" id="reference-list"><div class="ref-cit-blk half_rhythm" id="pone.0055859-Serhan1">1. <span class="mixed-citation">
Serhan C, Savill J (2005) <span class="ref-title">Resolution of inflammation: the beginning programs the end</span>. <span class="ref-journal">Nature Immunol</span>
<span class="ref-vol">6</span>: 1191–1197. [<a href="/pubmed/16369558" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3568070&amp;issue-id=219104&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nature+Immunol&amp;title=Resolution+of+inflammation:+the+beginning+programs+the+end&amp;author=C+Serhan&amp;author=J+Savill&amp;volume=6&amp;publication_year=2005&amp;pages=1191-1197&amp;pmid=16369558&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3568070&amp;issue-id=219104&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0055859-Gilroy1">2. <span class="mixed-citation">
Gilroy D, Lawrence T, Perretti M, Rossi A (2004) <span class="ref-title">Inflammatory resolution: new opportunities for drug discovery</span>. <span class="ref-journal">Nat Rev Drug Discov</span>
<span class="ref-vol">3</span>: 401–416. [<a href="/pubmed/15136788" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3568070&amp;issue-id=219104&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nat+Rev+Drug+Discov&amp;title=Inflammatory+resolution:+new+opportunities+for+drug+discovery&amp;author=D+Gilroy&amp;author=T+Lawrence&amp;author=M+Perretti&amp;author=A+Rossi&amp;volume=3&amp;publication_year=2004&amp;pages=401-416&amp;pmid=15136788&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3568070&amp;issue-id=219104&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0055859-Nathan1">3. <span class="mixed-citation">
Nathan C, Ding A (2010) <span class="ref-title">Nonresolving inflammation</span>. <span class="ref-journal">Cell</span>
<span class="ref-vol">140</span>: 871–882. [<a href="/pubmed/20303877" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3568070&amp;issue-id=219104&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cell&amp;title=Nonresolving+inflammation&amp;author=C+Nathan&amp;author=A+Ding&amp;volume=140&amp;publication_year=2010&amp;pages=871-882&amp;pmid=20303877&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3568070&amp;issue-id=219104&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0055859-Bates1">4. <span class="mixed-citation">
Bates D, Fawcett P, Shaw D, Weightman D (1978) <span class="ref-title">Polyunsaturated fatty acids in the treatment of acute remitting multiple sclerosis</span>. <span class="ref-journal">Br Med J</span>
<span class="ref-vol">2</span>: 1390–1391. <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC1608620/">PMC free article</a>]</span> [<a href="/pubmed/363236" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3568070&amp;issue-id=219104&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Br+Med+J&amp;title=Polyunsaturated+fatty+acids+in+the+treatment+of+acute+remitting+multiple+sclerosis&amp;author=D+Bates&amp;author=P+Fawcett&amp;author=D+Shaw&amp;author=D+Weightman&amp;volume=2&amp;publication_year=1978&amp;pages=1390-1391&amp;pmid=363236&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3568070&amp;issue-id=219104&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0055859-Yao1">5. <span class="mixed-citation">
Yao C, Sakata D, Esaki Y, Li Y, Matsuoka T, et al. (2009) <span class="ref-title">Prostaglandin E2-EP4 signaling promotes immune inflammation through Th1 cell differentiation and Th17 cell expansion</span>. <span class="ref-journal">Nat Med</span>
<span class="ref-vol">15</span>: 633–640. [<a href="/pubmed/19465928" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3568070&amp;issue-id=219104&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nat+Med&amp;title=Prostaglandin+E2-EP4+signaling+promotes+immune+inflammation+through+Th1+cell+differentiation+and+Th17+cell+expansion&amp;author=C+Yao&amp;author=D+Sakata&amp;author=Y+Esaki&amp;author=Y+Li&amp;author=T+Matsuoka&amp;volume=15&amp;publication_year=2009&amp;pages=633-640&amp;pmid=19465928&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3568070&amp;issue-id=219104&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0055859-Greco1">6. <span class="mixed-citation">
Greco A, Minghetti L, Sette G, Fieschi C, Levi G (1999) <span class="ref-title">Cerebrospinal fluid isoprostane shows oxidative stress in patients with multiple sclerosis</span>. <span class="ref-journal">Neurology</span>
<span class="ref-vol">53</span>: 1876–1879. [<a href="/pubmed/10563647" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3568070&amp;issue-id=219104&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Neurology&amp;title=Cerebrospinal+fluid+isoprostane+shows+oxidative+stress+in+patients+with+multiple+sclerosis&amp;author=A+Greco&amp;author=L+Minghetti&amp;author=G+Sette&amp;author=C+Fieschi&amp;author=G+Levi&amp;volume=53&amp;publication_year=1999&amp;pages=1876-1879&amp;pmid=10563647&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3568070&amp;issue-id=219104&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0055859-Chiang1">7. <span class="mixed-citation">
Chiang N, Bermudez E, Ridker P, Hurwitz S, Serhan C (2004) <span class="ref-title">Aspirin triggers antiinflammatory 15-epi-lipoxin A4 and inhibits thromboxane in a randomized human trial</span>. <span class="ref-journal">Proc Natl Acad Sci U S A</span>
<span class="ref-vol">101</span>: 15178–15183. <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC523452/">PMC free article</a>]</span> [<a href="/pubmed/15471991" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3568070&amp;issue-id=219104&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Proc+Natl+Acad+Sci+U+S+A&amp;title=Aspirin+triggers+antiinflammatory+15-epi-lipoxin+A4+and+inhibits+thromboxane+in+a+randomized+human+trial&amp;author=N+Chiang&amp;author=E+Bermudez&amp;author=P+Ridker&amp;author=S+Hurwitz&amp;author=C+Serhan&amp;volume=101&amp;publication_year=2004&amp;pages=15178-15183&amp;pmid=15471991&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3568070&amp;issue-id=219104&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0055859-Schwab1">8. <span class="mixed-citation">
Schwab J, Chiang N, Arita M, Serhan C (2007) <span class="ref-title">Resolvin E1 and protectin D1 activate inflammation-resolution programmes</span>. <span class="ref-journal">Nature</span>
<span class="ref-vol">447</span>: 869–874. <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2757086/">PMC free article</a>]</span> [<a href="/pubmed/17568749" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3568070&amp;issue-id=219104&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nature&amp;title=Resolvin+E1+and+protectin+D1+activate+inflammation-resolution+programmes&amp;author=J+Schwab&amp;author=N+Chiang&amp;author=M+Arita&amp;author=C+Serhan&amp;volume=447&amp;publication_year=2007&amp;pages=869-874&amp;pmid=17568749&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3568070&amp;issue-id=219104&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0055859-Polman1">9. <span class="mixed-citation">
Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, et al. (2011) <span class="ref-title">Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria</span>. <span class="ref-journal">Ann Neurol</span>
<span class="ref-vol">69</span>: 292–302. <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3084507/">PMC free article</a>]</span> [<a href="/pubmed/21387374" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3568070&amp;issue-id=219104&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Ann+Neurol&amp;title=Diagnostic+criteria+for+multiple+sclerosis:+2010+revisions+to+the+McDonald+criteria&amp;author=CH+Polman&amp;author=SC+Reingold&amp;author=B+Banwell&amp;author=M+Clanet&amp;author=JA+Cohen&amp;volume=69&amp;publication_year=2011&amp;pages=292-302&amp;pmid=21387374&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3568070&amp;issue-id=219104&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0055859-Hassan1">10. <span class="mixed-citation">
Hassan IR, Gronert K (2009) <span class="ref-title">Acute changes in dietary omega-3 and omega-6 polyunsaturated fatty acids have a pronounced impact on survival following ischemic renal injury and formation of renoprotective docosahexaenoic acid-derived protectin D1</span>. <span class="ref-journal">J Immunol</span>
<span class="ref-vol">182</span>: 3223–3232. [<a href="/pubmed/19234220" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3568070&amp;issue-id=219104&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Immunol&amp;title=Acute+changes+in+dietary+omega-3+and+omega-6+polyunsaturated+fatty+acids+have+a+pronounced+impact+on+survival+following+ischemic+renal+injury+and+formation+of+renoprotective+docosahexaenoic+acid-derived+protectin+D1&amp;author=IR+Hassan&amp;author=K+Gronert&amp;volume=182&amp;publication_year=2009&amp;pages=3223-3232&amp;pmid=19234220&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3568070&amp;issue-id=219104&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0055859-Sapieha1">11. <span class="mixed-citation">
Sapieha P, Stahl A, Chen J, Seaward MR, Willett KL, et al. (2007) <span class="ref-title">5-Lipoxygenase metabolite 4-HDHA is a mediator of the antiangiogenic effect of omega-3 polyunsaturated fatty acids</span>. <span class="ref-journal">Sci Transl Med</span>
<span class="ref-vol">3</span>: 69ra12. <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3711031/">PMC free article</a>]</span> [<a href="/pubmed/21307302" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3568070&amp;issue-id=219104&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Sci+Transl+Med&amp;title=5-Lipoxygenase+metabolite+4-HDHA+is+a+mediator+of+the+antiangiogenic+effect+of+omega-3+polyunsaturated+fatty+acids&amp;author=P+Sapieha&amp;author=A+Stahl&amp;author=J+Chen&amp;author=MR+Seaward&amp;author=KL+Willett&amp;volume=3&amp;publication_year=2007&amp;pages=69ra12&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3568070&amp;issue-id=219104&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0055859-vonMoltke1">12. <span class="mixed-citation">
von Moltke J, Trinidad NJ, Moayeri M, Kintzer AF, Wang SB, et al. (2012) <span class="ref-title">Rapid induction of inflammatory lipid mediators by the inflammasome in vivo</span>. <span class="ref-journal">Nature</span>
<span class="ref-vol">490</span>: 107–111. <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3465483/">PMC free article</a>]</span> [<a href="/pubmed/22902502" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3568070&amp;issue-id=219104&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nature&amp;title=Rapid+induction+of+inflammatory+lipid+mediators+by+the+inflammasome+in+vivo&amp;author=J+von+Moltke&amp;author=NJ+Trinidad&amp;author=M+Moayeri&amp;author=AF+Kintzer&amp;author=SB+Wang&amp;volume=490&amp;publication_year=2012&amp;pages=107-111&amp;pmid=22902502&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3568070&amp;issue-id=219104&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0055859-Leedom1">13. <span class="mixed-citation">
Leedom AJ, Sullivan AB, Dong B, Lau D, Gronert K (2010) <span class="ref-title">Endogenous LXA4 circuits are determinants of pathological angiogenesis in response to chronic injury</span>. <span class="ref-journal">Am J Pathol</span>
<span class="ref-vol">176</span>: 74–84. <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2797871/">PMC free article</a>]</span> [<a href="/pubmed/20008149" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3568070&amp;issue-id=219104&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Am+J+Pathol&amp;title=Endogenous+LXA4+circuits+are+determinants+of+pathological+angiogenesis+in+response+to+chronic+injury&amp;author=AJ+Leedom&amp;author=AB+Sullivan&amp;author=B+Dong&amp;author=D+Lau&amp;author=K+Gronert&amp;volume=176&amp;publication_year=2010&amp;pages=74-84&amp;pmid=20008149&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3568070&amp;issue-id=219104&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0055859-GonzalezPeriz1">14. <span class="mixed-citation">
Gonzalez-Periz A, Horrillo R, Ferre N, Gronert K, Dong B, et al. (2009) <span class="ref-title">Obesity-induced insulin resistance and hepatic steatosis are alleviated by omega-3 fatty acids: a role for resolvins and protectins</span>. <span class="ref-journal">FASEB J</span>
<span class="ref-vol">23</span>: 1946–1957. <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2698663/">PMC free article</a>]</span> [<a href="/pubmed/19211925" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3568070&amp;issue-id=219104&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=FASEB+J&amp;title=Obesity-induced+insulin+resistance+and+hepatic+steatosis+are+alleviated+by+omega-3+fatty+acids:+a+role+for+resolvins+and+protectins&amp;author=A+Gonzalez-Periz&amp;author=R+Horrillo&amp;author=N+Ferre&amp;author=K+Gronert&amp;author=B+Dong&amp;volume=23&amp;publication_year=2009&amp;pages=1946-1957&amp;pmid=19211925&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3568070&amp;issue-id=219104&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0055859-Awad1">15. <span class="mixed-citation">
Awad A, Hemmer B, Hartung HP, Kieseier B, Bennett JL, et al. (2010) <span class="ref-title">Analyses of cerebrospinal fluid in the diagnosis and monitoring of multiple sclerosis</span>. <span class="ref-journal">J Neuroimmunol</span>
<span class="ref-vol">219</span>: 1–7. [<a href="/pubmed/19782408" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3568070&amp;issue-id=219104&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Neuroimmunol&amp;title=Analyses+of+cerebrospinal+fluid+in+the+diagnosis+and+monitoring+of+multiple+sclerosis&amp;author=A+Awad&amp;author=B+Hemmer&amp;author=HP+Hartung&amp;author=B+Kieseier&amp;author=JL+Bennett&amp;volume=219&amp;publication_year=2010&amp;pages=1-7&amp;pmid=19782408&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3568070&amp;issue-id=219104&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0055859-Spite1">16. <span class="mixed-citation">
Spite M, Summers L, Porter T, Srivastava S, Bhatnagar A, et al. (2009) <span class="ref-title">Resolvin D1 controls inflammation initiated by glutathione-lipid conjugates formed during oxidative stress</span>. <span class="ref-journal">Br J Pharmacol</span>
<span class="ref-vol">158</span>: 1062–1073. <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2785528/">PMC free article</a>]</span> [<a href="/pubmed/19422383" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3568070&amp;issue-id=219104&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Br+J+Pharmacol&amp;title=Resolvin+D1+controls+inflammation+initiated+by+glutathione-lipid+conjugates+formed+during+oxidative+stress&amp;author=M+Spite&amp;author=L+Summers&amp;author=T+Porter&amp;author=S+Srivastava&amp;author=A+Bhatnagar&amp;volume=158&amp;publication_year=2009&amp;pages=1062-1073&amp;pmid=19422383&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3568070&amp;issue-id=219104&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0055859-Morris1">17. <span class="mixed-citation">
Morris T, Stables M, Colville-Nash P, Newson J, Bellingan G, et al. (2010) <span class="ref-title">Dichotomy in duration and severity of acute inflammatory responses in humans arising from differentially expressed proresolution pathways</span>. <span class="ref-journal">Proc Natl Acad Sci U S A</span>
<span class="ref-vol">107</span>: 8842–8847. <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2889345/">PMC free article</a>]</span> [<a href="/pubmed/20421472" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3568070&amp;issue-id=219104&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Proc+Natl+Acad+Sci+U+S+A&amp;title=Dichotomy+in+duration+and+severity+of+acute+inflammatory+responses+in+humans+arising+from+differentially+expressed+proresolution+pathways&amp;author=T+Morris&amp;author=M+Stables&amp;author=P+Colville-Nash&amp;author=J+Newson&amp;author=G+Bellingan&amp;volume=107&amp;publication_year=2010&amp;pages=8842-8847&amp;pmid=20421472&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3568070&amp;issue-id=219104&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0055859-Levy1">18. <span class="mixed-citation">
Levy BD, Clish CB, Schmidt B, Gronert K, Serhan CN (2001) <span class="ref-title">Lipid mediator class switching during acute inflammation: signals in resolution</span>. <span class="ref-journal">Nat Immunol</span>
<span class="ref-vol">2</span>: 612–619. [<a href="/pubmed/11429545" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3568070&amp;issue-id=219104&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nat+Immunol&amp;title=Lipid+mediator+class+switching+during+acute+inflammation:+signals+in+resolution&amp;author=BD+Levy&amp;author=CB+Clish&amp;author=B+Schmidt&amp;author=K+Gronert&amp;author=CN+Serhan&amp;volume=2&amp;publication_year=2001&amp;pages=612-619&amp;pmid=11429545&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3568070&amp;issue-id=219104&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0055859-Uderhardt1">19. <span class="mixed-citation">
Uderhardt S, Herrmann M, Oskolkova OV, Aschermann S, Bicker W, et al. (2012) <span class="ref-title">12/15-lipoxygenase orchestrates the clearance of apoptotic cells and maintains immunologic tolerance</span>. <span class="ref-journal">Immunity</span>
<span class="ref-vol">36</span>: 834–846. [<a href="/pubmed/22503541" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3568070&amp;issue-id=219104&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Immunity&amp;title=12/15-lipoxygenase+orchestrates+the+clearance+of+apoptotic+cells+and+maintains+immunologic+tolerance&amp;author=S+Uderhardt&amp;author=M+Herrmann&amp;author=OV+Oskolkova&amp;author=S+Aschermann&amp;author=W+Bicker&amp;volume=36&amp;publication_year=2012&amp;pages=834-846&amp;pmid=22503541&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3568070&amp;issue-id=219104&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div></div></div><div style="display: none; width: 200px; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true" class="ui-helper-reset ui-ncbipopper-wrapper ui-ncbilinksmenu"><ul id="ui-ncbiinpagenav-2" style=""><li><a href="#ui-ncbiinpagenav-heading-3">Associated Data</a></li><li><a href="#idm140089062296448title">Abstract</a></li><li><a href="#s1title">Introduction</a></li><li><a href="#s2title">Methods</a></li><li><a href="#s3title">Results</a></li><li><a href="#s4title">Discussion</a></li><li><a href="#s5title">Supporting Information</a></li><li><a href="#idm140089076814864title">Acknowledgments</a></li><li><a href="#idm140089077546400title">Funding Statement</a></li><li><a href="#idm140089076814240title">References</a></li></ul></div></div><!--post-content--><div class="courtesy-note whole_rhythm small"><hr>Articles from <span class="acknowledgment-journal-title">PLoS ONE</span> are provided here courtesy of <strong>Public Library of Science</strong></div></div>
            
            
        
            
        </div>
        <!-- Book content -->
    </div>
    
    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            
        </div>
        
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><div class="format-menu"><h2>Formats:</h2><ul><li class="selected">Article</li> | <li><a href="/pmc/articles/PMC3568070/?report=reader">PubReader</a></li> | <li class="epub-link"><a href="/pmc/articles/PMC3568070/epub/">ePub (beta)</a></li> | <li><a href="/pmc/articles/PMC3568070/pdf/pone.0055859.pdf">PDF (373K)</a></li> | <li><a href="#" data-citationid="PMC3568070" class="citationexporter ctxp" role="button" aria-expanded="false" aria-haspopup="true">Citation</a></li></ul></div></div><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="share-buttons"><h2>Share</h2><ul><li class="facebook"><a href="https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3568070%2F" role="button" aria-expanded="false" aria-haspopup="true" target="_blank"><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/img/4047626" alt="Share on Facebook">
                             Facebook
                        </a></li><li class="twitter"><a href="https://twitter.com/intent/tweet?url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3568070%2F&amp;text=Proresolution%20Lipid%20Mediators%20in%20Multiple%20Sclerosis%20%E2%80%94%20Differential%2C%20Disease%20Severity-Dependent%20Synthesis%20%E2%80%94%20A%20Clinical%20Pilot%20Trial" role="button" aria-expanded="false" aria-haspopup="true" target="_blank"><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/img/4047627" alt="Share on Twitter">
                             Twitter
                        </a></li><li class="gplus"><a href="https://plus.google.com/share?url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3568070%2F" role="button" aria-expanded="false" aria-haspopup="true" target="_blank"><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/img/4047628" alt="Share on Google Plus">
                             Google+
                        </a></li></ul></div>
        
        <div id="ajax-portlets" data-pmid="23409068" data-aiid="3568070" data-aid="3568070" data-iid="219104" data-domainid="440" data-domain="plosone" data-accid="PMC3568070" data-md5="182c5d67fa8cc708c5ec45ff753f9991">

<div>





</div>   
    </div>
                
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script>
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>



<div id="body-link-poppers"><div id="body-link-popper-pone.0055859-Serhan1" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true"><span class="invert">Review</span> Resolution of inflammation: the beginning programs the end.<div class="authors">Serhan CN, Savill J</div><div class="citation">Nat Immunol. 2005 Dec; 6(12):1191-7.</div><p>[<a href="/pubmed/16369558/" ref="reftype=pubmed&amp;article-id=3568070&amp;issue-id=219104&amp;journal-id=440&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">PubMed</a>] [<a href="#pone.0055859-Serhan1">Ref list</a>]</p></div><div id="body-link-popper-pone.0055859-Nathan1" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true"><span class="invert">Review</span> Nonresolving inflammation.<div class="authors">Nathan C, Ding A</div><div class="citation">Cell. 2010 Mar 19; 140(6):871-82.</div><p>[<a href="/pubmed/20303877/" ref="reftype=pubmed&amp;article-id=3568070&amp;issue-id=219104&amp;journal-id=440&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">PubMed</a>] [<a href="#pone.0055859-Nathan1">Ref list</a>]</p></div><div id="body-link-popper-pone.0055859-Bates1" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Polyunsaturated fatty acids in treatment of acute remitting multiple sclerosis.<div class="authors">Bates D, Fawcett PR, Shaw DA, Weightman D</div><div class="citation">Br Med J. 1978 Nov 18; 2(6149):1390-1.</div><p>[<a href="/pubmed/363236/" ref="reftype=pubmed&amp;article-id=3568070&amp;issue-id=219104&amp;journal-id=440&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">PubMed</a>] [<a href="#pone.0055859-Bates1">Ref list</a>]</p></div><div id="body-link-popper-pone.0055859-Yao1" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Prostaglandin E2-EP4 signaling promotes immune inflammation through Th1 cell differentiation and Th17 cell expansion.<div class="authors">Yao C, Sakata D, Esaki Y, Li Y, Matsuoka T, Kuroiwa K, Sugimoto Y, Narumiya S</div><div class="citation">Nat Med. 2009 Jun; 15(6):633-40.</div><p>[<a href="/pubmed/19465928/" ref="reftype=pubmed&amp;article-id=3568070&amp;issue-id=219104&amp;journal-id=440&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">PubMed</a>] [<a href="#pone.0055859-Yao1">Ref list</a>]</p></div><div id="body-link-popper-pone.0055859-Greco1" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Cerebrospinal fluid isoprostane shows oxidative stress in patients with multiple sclerosis.<div class="authors">Greco A, Minghetti L, Sette G, Fieschi C, Levi G</div><div class="citation">Neurology. 1999 Nov 10; 53(8):1876-9.</div><p>[<a href="/pubmed/10563647/" ref="reftype=pubmed&amp;article-id=3568070&amp;issue-id=219104&amp;journal-id=440&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">PubMed</a>] [<a href="#pone.0055859-Greco1">Ref list</a>]</p></div><div id="body-link-popper-pone.0055859-Chiang1" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Aspirin triggers antiinflammatory 15-epi-lipoxin A4 and inhibits thromboxane in a randomized human trial.<div class="authors">Chiang N, Bermudez EA, Ridker PM, Hurwitz S, Serhan CN</div><div class="citation">Proc Natl Acad Sci U S A. 2004 Oct 19; 101(42):15178-83.</div><p>[<a href="/pubmed/15471991/" ref="reftype=pubmed&amp;article-id=3568070&amp;issue-id=219104&amp;journal-id=440&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">PubMed</a>] [<a href="#pone.0055859-Chiang1">Ref list</a>]</p></div><div id="body-link-popper-pone.0055859-Schwab1" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Resolvin E1 and protectin D1 activate inflammation-resolution programmes.<div class="authors">Schwab JM, Chiang N, Arita M, Serhan CN</div><div class="citation">Nature. 2007 Jun 14; 447(7146):869-74.</div><p>[<a href="/pubmed/17568749/" ref="reftype=pubmed&amp;article-id=3568070&amp;issue-id=219104&amp;journal-id=440&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">PubMed</a>] [<a href="#pone.0055859-Schwab1">Ref list</a>]</p></div><div id="body-link-popper-pone.0055859-Gilroy1" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true"><span class="invert">Review</span> Inflammatory resolution: new opportunities for drug discovery.<div class="authors">Gilroy DW, Lawrence T, Perretti M, Rossi AG</div><div class="citation">Nat Rev Drug Discov. 2004 May; 3(5):401-16.</div><p>[<a href="/pubmed/15136788/" ref="reftype=pubmed&amp;article-id=3568070&amp;issue-id=219104&amp;journal-id=440&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">PubMed</a>] [<a href="#pone.0055859-Gilroy1">Ref list</a>]</p></div><div id="body-link-popper-pone.0055859-Polman1" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria.<div class="authors">Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O'Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS</div><div class="citation">Ann Neurol. 2011 Feb; 69(2):292-302.</div><p>[<a href="/pubmed/21387374/" ref="reftype=pubmed&amp;article-id=3568070&amp;issue-id=219104&amp;journal-id=440&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">PubMed</a>] [<a href="#pone.0055859-Polman1">Ref list</a>]</p></div><div id="body-link-popper-pone.0055859-Hassan1" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Acute changes in dietary omega-3 and omega-6 polyunsaturated fatty acids have a pronounced impact on survival following ischemic renal injury and formation of renoprotective docosahexaenoic acid-derived protectin D1.<div class="authors">Hassan IR, Gronert K</div><div class="citation">J Immunol. 2009 Mar 1; 182(5):3223-32.</div><p>[<a href="/pubmed/19234220/" ref="reftype=pubmed&amp;article-id=3568070&amp;issue-id=219104&amp;journal-id=440&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">PubMed</a>] [<a href="#pone.0055859-Hassan1">Ref list</a>]</p></div><div id="body-link-popper-pone.0055859-GonzalezPeriz1" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Obesity-induced insulin resistance and hepatic steatosis are alleviated by omega-3 fatty acids: a role for resolvins and protectins.<div class="authors">González-Périz A, Horrillo R, Ferré N, Gronert K, Dong B, Morán-Salvador E, Titos E, Martínez-Clemente M, López-Parra M, Arroyo V, Clària J</div><div class="citation">FASEB J. 2009 Jun; 23(6):1946-57.</div><p>[<a href="/pubmed/19211925/" ref="reftype=pubmed&amp;article-id=3568070&amp;issue-id=219104&amp;journal-id=440&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">PubMed</a>] [<a href="#pone.0055859-GonzalezPeriz1">Ref list</a>]</p></div><div id="body-link-popper-pone.0055859-Awad1" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true"><span class="invert">Review</span> Analyses of cerebrospinal fluid in the diagnosis and monitoring of multiple sclerosis.<div class="authors">Awad A, Hemmer B, Hartung HP, Kieseier B, Bennett JL, Stuve O</div><div class="citation">J Neuroimmunol. 2010 Feb 26; 219(1-2):1-7.</div><p>[<a href="/pubmed/19782408/" ref="reftype=pubmed&amp;article-id=3568070&amp;issue-id=219104&amp;journal-id=440&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">PubMed</a>] [<a href="#pone.0055859-Awad1">Ref list</a>]</p></div><div id="body-link-popper-pone.0055859-Spite1" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Resolvin D1 controls inflammation initiated by glutathione-lipid conjugates formed during oxidative stress.<div class="authors">Spite M, Summers L, Porter TF, Srivastava S, Bhatnagar A, Serhan CN</div><div class="citation">Br J Pharmacol. 2009 Oct; 158(4):1062-73.</div><p>[<a href="/pubmed/19422383/" ref="reftype=pubmed&amp;article-id=3568070&amp;issue-id=219104&amp;journal-id=440&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">PubMed</a>] [<a href="#pone.0055859-Spite1">Ref list</a>]</p></div><div id="body-link-popper-pone.0055859-Morris1" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Dichotomy in duration and severity of acute inflammatory responses in humans arising from differentially expressed proresolution pathways.<div class="authors">Morris T, Stables M, Colville-Nash P, Newson J, Bellingan G, de Souza PM, Gilroy DW</div><div class="citation">Proc Natl Acad Sci U S A. 2010 May 11; 107(19):8842-7.</div><p>[<a href="/pubmed/20421472/" ref="reftype=pubmed&amp;article-id=3568070&amp;issue-id=219104&amp;journal-id=440&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">PubMed</a>] [<a href="#pone.0055859-Morris1">Ref list</a>]</p></div><div id="body-link-popper-pone.0055859-Levy1" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Lipid mediator class switching during acute inflammation: signals in resolution.<div class="authors">Levy BD, Clish CB, Schmidt B, Gronert K, Serhan CN</div><div class="citation">Nat Immunol. 2001 Jul; 2(7):612-9.</div><p>[<a href="/pubmed/11429545/" ref="reftype=pubmed&amp;article-id=3568070&amp;issue-id=219104&amp;journal-id=440&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">PubMed</a>] [<a href="#pone.0055859-Levy1">Ref list</a>]</p></div><div id="body-link-popper-pone.0055859-Uderhardt1" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">12/15-lipoxygenase orchestrates the clearance of apoptotic cells and maintains immunologic tolerance.<div class="authors">Uderhardt S, Herrmann M, Oskolkova OV, Aschermann S, Bicker W, Ipseiz N, Sarter K, Frey B, Rothe T, Voll R, Nimmerjahn F, Bochkov VN, Schett G, Krönke G</div><div class="citation">Immunity. 2012 May 25; 36(5):834-46.</div><p>[<a href="/pubmed/22503541/" ref="reftype=pubmed&amp;article-id=3568070&amp;issue-id=219104&amp;journal-id=440&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">PubMed</a>] [<a href="#pone.0055859-Uderhardt1">Ref list</a>]</p></div></div>
                        </div>
                        <div class="bottom">
                            
                            

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        <div class="ui-ncbiautocomplete-holder shadow ui-ncbiautocomplete-holder-clearfix" aria-live="assertive" style="display: none; top: 64px; left: 459px; width: 670px; z-index: 1001;"><ul class="ui-ncbiautocomplete-options" role="listbox" aria-activedescendant="term"></ul><div class="ui-ncbiautocomplete-actions shadow" style="display: block;"><a class="ui-ncbiautocomplete-link-pref" style="display: none;">Preferences</a><a href="#" class="ui-ncbiautocomplete-link-off ui-ncbiautocomplete-link-pref-right" style="display: block;">Turn off</a></div></div><div style="display: none; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true" class="ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic">External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.</div></div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript>&lt;img alt="statistics" src="/stat?jsdisabled=true&amp;amp;ncbi_db=pmc&amp;amp;ncbi_pdid=article&amp;amp;ncbi_acc=&amp;amp;ncbi_domain=plosone&amp;amp;ncbi_report=record&amp;amp;ncbi_type=fulltext&amp;amp;ncbi_objectid=&amp;amp;ncbi_pcid=/articles/PMC3568070/&amp;amp;ncbi_app=pmc" /&gt;</noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- 95B63906E70AD421_0000SID /projects/PMC/PMCViewer@4.46 ptpmc101 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/js/3879255/4121861/3818874/4168176/3821238/4117325/4087685/4072593/4076480/3921943/4105668/4065628.js" snapshot="pmc"></script>
<div class="ui-dialog ui-widget ui-widget-content ui-corner-all ui-front" style="display: none;" tabindex="-1" role="dialog" aria-describedby="epubDialog" aria-labelledby="ui-id-1"><div class="ui-dialog-titlebar ui-widget-header ui-corner-all ui-helper-clearfix"><span id="ui-id-1" class="ui-dialog-title">Making articles easier to read in PMC</span><button type="button" class="ui-button ui-widget ui-state-default ui-corner-all ui-button-icon-only ui-dialog-titlebar-close" role="button" title="Close"><span class="ui-button-icon-primary ui-icon ui-icon-closethick"></span><span class="ui-button-text">Close</span></button></div><div id="epubDialog" style="display: block;" class="ui-dialog-content ui-widget-content">  <p>We are experimenting with display styles that make it easier to read articles     in PMC.     Our first effort uses eBook readers, which have several "ease of reading"     features already built in.</p>  <p>These PMC articles are best viewed in the <em>iBooks     reader</em>. You may notice problems with the display of certain parts of an article     in other eReaders.</p>  <div class="ui-dialog-buttonpane ui-widget-content ui-helper-clearfix"><button id="cancelEpub" class="ui-state-default ui-corner-all">Cancel</button><button id="downloadEpub" style="float: left" class="ui-state-default ui-corner-all">Download article</button></div>          </div></div></body></htm
